<DOC>
	<DOCNO>NCT02005770</DOCNO>
	<brief_summary>Serious concern role anesthesia tumor recurrence considerably risen year , lack surrogate marker tumor spread make trial address issue difficult realize . In breast cancer patient CTC positivity recently recognize independent prognostic factor . In respect , postulate first step change number CTC general anesthesia would help determine effect anesthesia tumor marker .</brief_summary>
	<brief_title>Anesthesia Circulating Tumor Cells Breast Cancer</brief_title>
	<detailed_description>Patients primary breast cancer randomize either propofol sevoflurane anesthesia curative surgery . CTC determine pre- well postoperative phase kinetic CTC two group compare .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<mesh_term>Anesthetics</mesh_term>
	<mesh_term>Propofol</mesh_term>
	<mesh_term>Sevoflurane</mesh_term>
	<criteria>Inclusion criterion : &gt; Female Age 18 85 ASA IIII Primary breast cancer ( TNM stage = T13 , N02 , M0 ) Primary surgery Written inform consent Exclusion criterion : Metastatic breast cancer Other primary surgery ( recurrence , reconstruction ) Preoperative chemotherapy radiotherapy Autoimmune disease , HIV , active cancer , age &gt; 85 , ASA IV V Concomitant regional anesthesia Chronic opioids medication Any systemic immunosuppressive therapy Known hypersensitivity suspect allergy propofol , soya egg protein Known hypersensitivity volatile anesthetic ( malignant hyperthermia ) Pregnancy Breast feeding Non Germanspeaking patient Enrollment clinical trial course trial , 30 day prior begin 30 day completion</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>